North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Results
Looking for
Everolimus
found
10 matches
Open monograph to display formulary status
BNF Category
Everolimus
(Afinitor
®
, Votubia
®
)
Malignant disease and immunosuppression - Protein kinase inhibitors - 08.01.05
Links
Link to Drug Section
Link to document
Clinical Commissioning Policy Statement: Everolimus (Votubia®) for treatment of angiomyolipomas associated with tuberous sclerosis (08.01.05)
Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (08.01.05)
NICE TA348: Everolimus for preventing organ rejection in liver transplantation (08.01.05)
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (08.01.05)
NICE TA432: Everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment (08.01.05)
NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (08.01.05)
NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (08.01.05)
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (08.01.05)
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (08.01.05)